Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | CASP6 | P55212 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31538470 | 1.00 | LMNA (0.73) | LMNAKDM4EPOLBCASP6CYP1A2 | |
| SCHEMBL30292799 | 0.84 | LMNA (1.00) | LMNAKDM4EPOLBCASP6CYP1A2 | |
| SCHEMBL116001 | 0.84 | LMNA (1.00) | LMNAKDM4EPOLBCASP6CYP1A2 | |
| Hydrochloric Acid SCHEMBL2247003 | 0.83 | KDM4E (0.96) | LMNAKDM4EPOLBCASP6CYP1A2 | |
| SCHEMBL10259445 | 0.78 | CYP1A2 (0.68) | LMNAKDM4EPOLBCASP6CYP1A2 | |
| SCHEMBL31261751 | 0.76 | CYP1A2 (1.00) | LMNAKDM4EPOLBCASP6CYP1A2 | |
| SCHEMBL7014346 | 0.76 | PLAU (0.71) | LMNAKDM4EPOLBCASP6MEN1 | |
| SCHEMBL951793 | 0.76 | CYP1A2 (1.00) | LMNAKDM4EPOLBCASP6CYP1A2 | |
| SCHEMBL30081469 | 0.76 | CYP1A2 (1.00) | LMNAKDM4EPOLBCASP6CYP1A2 | |
| Proflavine SCHEMBL29600097 | 0.75 | KMT2A (1.00) | LMNAKDM4EPOLBCASP6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119842391-A | Preparation method of fluorescent nanoparticle and fluorescent nanoparticle prepared by same | 中国科学院大连化学物理研究所 | 2025-04-18 | — | — | CN | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| CN-116354879-A | Benzamide derivative and application thereof | 中国药科大学 | 2023-06-30 | — | — | CN | disclosed |
| EP-4010080-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| US-11209582-B2 | Composition, curable composition, cured film, near infrared cut filter, infrared transmitting filter, solid image pickup element, infrared sensor, and camera module | FUJIFILM CORPORATION (JP) | 2021-12-28 | — | — | US | disclosed |
| EP-3326715-B1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | CE PHARM CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| WO-2021028643-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | CE PHARM CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | CE PHARM CO., LTD. (CN) | 2019-05-02 | — | — | US | disclosed |
| US-20180207628-A1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2018-07-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-1425277-B8 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2036902-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| EP-1425277-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SmithKline Beecham P.L.C. (GB) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003022809-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | LMNA 2016/4885KDM4E 3923/4885POLB 4767/4885 |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | AOC1, AOC2, AOC3 | LMNA 4664/4885KDM4E 3660/4885POLB 1801/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | LMNA 3021/4885KDM4E 1156/4885POLB 2458/4885 |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | AOC1, AOC2, AOC3 | LMNA 4664/4885KDM4E 3660/4885POLB 1801/4885 |
| US-20180207628-A1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | AOC2, AOC1, AOC3 | LMNA 4691/4885KDM4E 4072/4885POLB 2211/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | LMNA 2720/4885KDM4E 3256/4885POLB 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.